Video

Dr. Kent Osborne Discusses the PRIME 2 Trial

C. Kent Osborne, MD, professor of medicine and molecular and cell biology, Baylor College of Medicine, discusses the impact of the results of the PRIME 2 trial, which looked at radiotherapy after surgery in women over 65 years old with breast cancer.

C. Kent Osborne, MD, professor of medicine and molecular and cell biology, Baylor College of Medicine, discusses the impact of the results of the PRIME 2 trial, which looked at radiotherapy after surgery in women over 65 years old with breast cancer.

Since this is not the only study that suggests that certain therapies can be avoided, Osborne feels that the results of this study will be practice changing. Even though the radiation therapy did reduce the risk of local recurrence, the differences were not great and the overall outcome was not different.

Osborne says that even in the rare case that a patient does recur in the breast without radiation, that patient can be salvaged very well by having another lumpectomy and radiation or by doing a mastectomy. However, this can be avoided in the majority of patients by not conducting radiation therapy.

<<<

View more from the 2013 SABCS Meeting

Related Videos
Sagar D. Sardesai, MBBS
DB-12
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP